|Bid||33.55 x 900|
|Ask||33.67 x 800|
|Day's range||32.26 - 34.40|
|52-week range||32.26 - 68.40|
|Beta (5Y monthly)||1.48|
|PE ratio (TTM)||N/A|
|Earnings date||02 Aug 2021 - 06 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||71.80|
Deciphera (DCPH) posts a narrower loss in the first quarter while sales beat on the encouraging uptake of Qinlock.
At this time, I would like to hand the conference over to Jen Robinson, Vice President of Investor Relations. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Dan Martin, Chief Commercial Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 1.85% and 8.89%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?